In hepatocellular carcinoma (HCC), IGF2BP3 prevents ferroptosis following sorafenib treatment by modifying m6A and increasing the stability of NRF2 mRNA, which is closely linked to tumor growth and poor prognosis in HCC (Lu et al., 2022). This evidence concerns the gene IGF2BP3 and hepatocellular carcinoma.